Campbell & CO Investment Adviser LLC Boosts Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Campbell & CO Investment Adviser LLC increased its holdings in Novo Nordisk A/S by 791.2% in Q1, acquiring 39,923 additional shares, bringing their total to 44,969 shares worth approximately $3.12 million.
• Novo Nordisk A/S recently reported earnings of $0.97 per share, exceeding expectations, with quarterly revenue of $11.69 billion, while analysts project an annual EPS of 3.84.
• The company announced a semi-annual dividend of $0.4119 per share, reflecting a 240.0% yield, and has a current payout ratio of 22.53%.

Campbell & CO Investment Adviser LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 791.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,969 shares of the company's stock after acquiring an additional 39,923 shares during the quarter. Campbell & CO Investment Adviser LLC's holdings in Novo Nordisk A/S were worth $3,123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Copeland Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $29,000. Stone House Investment Management LLC bought a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $30,000. Finally, Disciplina Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock worth $33,000 after purchasing an additional 297 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 2.6%

NVO stock opened at $56.8910 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $254.02 billion, a PE ratio of 15.63, a PEG ratio of 1.98 and a beta of 0.63. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $139.74. The stock has a 50-day simple moving average of $62.57 and a two-hundred day simple moving average of $69.33.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's payout ratio is presently 22.53%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on NVO shares. HSBC cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price on the stock. in a research note on Thursday, July 31st. UBS Group cut Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Hsbc Global Res cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Three analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.